Solid Tumor – Pipeline Review, H1 2012

Document Sample
Solid Tumor – Pipeline Review, H1 2012 Powered By Docstoc
					Solid Tumor – Pipeline Review, H1 2012




                         Solid Tumor – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1622IDB
                                                                                            Publication Date: January 2012




Solid Tumor – Pipeline Review, H1 2012                                                     GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Solid Tumor – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 11
    List of Figures .............................................................................................................................................................................. 21
Introduction....................................................................................................................................................................................... 22
    Global Markets Direct Report Coverage ...................................................................................................................................... 22
Solid Tumor Overview ...................................................................................................................................................................... 23
Therapeutics Development............................................................................................................................................................... 24
    An Overview of Pipeline Products for Solid Tumor ...................................................................................................................... 24
Solid Tumor Therapeutics under Development by Companies ........................................................................................................ 26
Solid Tumor Therapeutics under Investigation by Universities/Institutes.......................................................................................... 47
Late Stage Products ......................................................................................................................................................................... 60
    Comparative Analysis .................................................................................................................................................................. 60
Mid Clinical Stage Products.............................................................................................................................................................. 61
    Comparative Analysis .................................................................................................................................................................. 61
Early Clinical Stage Products ........................................................................................................................................................... 62
    Comparative Analysis .................................................................................................................................................................. 62
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 63
    Comparative Analysis .................................................................................................................................................................. 63
Solid Tumor Therapeutics – Products under Development by Companies ...................................................................................... 64
Solid Tumor Therapeutics – Products under Investigation by Universities/Institutes...................................................................... 117
Companies Involved in Solid Tumor Therapeutics Development ................................................................................................... 166
    Bristol-Myers Squibb Company ................................................................................................................................................. 166
    Genzyme Corporation ............................................................................................................................................................... 167
    Johnson & Johnson ................................................................................................................................................................... 168
    Boehringer Ingelheim GmbH ..................................................................................................................................................... 169
    F. Hoffmann-La Roche Ltd. ....................................................................................................................................................... 170
    Kyowa Hakko Kirin Co., Ltd. ...................................................................................................................................................... 171
    Abbott Laboratories ................................................................................................................................................................... 172
    Biogen Idec Inc. ......................................................................................................................................................................... 173
    Shionogi & Co., Ltd.................................................................................................................................................................... 174
    Amgen Inc. ................................................................................................................................................................................ 175
    Sanofi-Aventis ........................................................................................................................................................................... 176
    Adherex Technologies Inc. ........................................................................................................................................................ 177
    AstraZeneca PLC ...................................................................................................................................................................... 178
    Eli Lilly and Company ................................................................................................................................................................ 179
    GlaxoSmithKline plc .................................................................................................................................................................. 180
    Seattle Genetics, Inc. ................................................................................................................................................................ 181
    Tekmira Pharmaceuticals Corp. ................................................................................................................................................ 182
    Genentech, Inc. ......................................................................................................................................................................... 183
    Nektar Therapeutics .................................................................................................................................................................. 185
    MedImmune LLC ....................................................................................................................................................................... 186
    Gilead Sciences, Inc. ................................................................................................................................................................. 187



Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Solid Tumor – Pipeline Review, H1 2012



    Biotest AG ................................................................................................................................................................................. 188
    Daiichi Sankyo Company, Ltd.................................................................................................................................................... 189
    Merck & Co., Inc. ....................................................................................................................................................................... 190
    Dainippon Sumitomo Pharma Co., Ltd. ..................................................................................................................................... 192
    Cangene Corporation ................................................................................................................................................................ 193
    Oxford BioMedica plc ................................................................................................................................................................ 194
    Micromet, Inc. ............................................................................................................................................................................ 195
    Scil Proteins GmbH ................................................................................................................................................................... 196
    Infinity Pharmaceuticals, Inc. ..................................................................................................................................................... 197
    Takeda Pharmaceutical Company Limited ................................................................................................................................ 198
    YM BioSciences Inc................................................................................................................................................................... 199
    Light Sciences Oncology, Inc. ................................................................................................................................................... 200
    Ipsen S.A. .................................................................................................................................................................................. 201
    Nanotherapeutics, Inc................................................................................................................................................................ 202
    Prolexys Pharmaceuticals, Inc................................................................................................................................................... 203
    Bio-Path Holdings, Inc. .............................................................................................................................................................. 204
    Ambrilia Biopharma Inc. ............................................................................................................................................................ 205
    Aposense Ltd............................................................................................................................................................................. 206
    ZIOPHARM Oncology, Inc. ........................................................................................................................................................ 207
    Millennium Pharmaceuticals, Inc. .............................................................................................................................................. 208
    Novartis AG ............................................................................................................................................................................... 209
    ImClone Systems Incorporated ................................................................................................................................................. 211
    Astellas Pharma Inc................................................................................................................................................................... 212
    BioMarin Pharmaceutical Inc. .................................................................................................................................................... 213
    Cephalon, Inc. ........................................................................................................................................................................... 214
    Chong Kun Dang Pharmaceutical ............................................................................................................................................. 215
    Chugai Pharmaceutical Co. Ltd ................................................................................................................................................. 216
    Daewoong Pharmaceutical Co., Ltd. ......................................................................................................................................... 217
    Eisai Co., Ltd. ............................................................................................................................................................................ 218
    Genta Incorporated.................................................................................................................................................................... 219
    GTC Biotherapeutics, Inc. ......................................................................................................................................................... 220
    ImmunoGen, Inc. ....................................................................................................................................................................... 221
    Kowa Company, Ltd. ................................................................................................................................................................. 222
    Nippon Kayaku Co., Ltd............................................................................................................................................................. 223
    Ono Pharmaceutical Co., Ltd..................................................................................................................................................... 224
    OSI Pharmaceuticals, Inc. ......................................................................................................................................................... 225
    Pfizer Inc.................................................................................................................................................................................... 226
    Sunesis Pharmaceuticals, Inc.................................................................................................................................................... 228
    SuperGen, Inc. .......................................................................................................................................................................... 229
    Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................. 230
    Takara Holdings Inc................................................................................................................................................................... 231
    Teva Pharmaceutical Industries Limited .................................................................................................................................... 232
    Cell Therapeutics, Inc. ............................................................................................................................................................... 233
    Genmab A/S .............................................................................................................................................................................. 234


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Solid Tumor – Pipeline Review, H1 2012



    Progenics Pharmaceuticals, Inc. ............................................................................................................................................... 235
    Enzon Pharmaceuticals, Inc. ..................................................................................................................................................... 236
    Santaris Pharma A/S ................................................................................................................................................................. 237
    Silence Therapeutics plc. .......................................................................................................................................................... 238
    Calando Pharmaceuticals, Inc. .................................................................................................................................................. 239
    Exelixis, Inc................................................................................................................................................................................ 240
    Aduro BioTech ........................................................................................................................................................................... 241
    Cyclacel Pharmaceuticals Inc. ................................................................................................................................................... 242
    Celgene Corporation ................................................................................................................................................................. 243
    Onyx Pharmaceuticals, Inc. ....................................................................................................................................................... 244
    Bayer AG ................................................................................................................................................................................... 245
    Incyte Corporation ..................................................................................................................................................................... 246
    Geron Corporation ..................................................................................................................................................................... 247
    MannKind Corporation............................................................................................................................................................... 248
    Merck KGaA .............................................................................................................................................................................. 249
    Access Pharmaceuticals, Inc. .................................................................................................................................................... 250
    4SC AG ..................................................................................................................................................................................... 251
    EntreMed, Inc. ........................................................................................................................................................................... 252
    EpiCept Corporation .................................................................................................................................................................. 253
    Genesis Research and Development Corporation Ltd. ............................................................................................................. 254
    Hana Biosciences, Inc. .............................................................................................................................................................. 255
    Celldex Therapeutics, Inc. ......................................................................................................................................................... 256
    AEterna Zentaris Inc. ................................................................................................................................................................. 257
    ImmunoCellular Therapeutics, Ltd. ............................................................................................................................................ 258
    Ariad Pharmaceuticals, Inc. ....................................................................................................................................................... 259
    Lorus Therapeutics Inc .............................................................................................................................................................. 260
    Marshall Edwards, Inc. .............................................................................................................................................................. 261
    MediciNova, Inc. ........................................................................................................................................................................ 262
    Basilea Pharmaceutica Ltd. ....................................................................................................................................................... 263
    MethylGene Inc ......................................................................................................................................................................... 264
    Bionomics Limited ..................................................................................................................................................................... 265
    MultiCell Technologies, Inc. ....................................................................................................................................................... 266
    Circadian Technologies Limited................................................................................................................................................. 267
    Oncolytics Biotech Inc. .............................................................................................................................................................. 268
    Oncothyreon Inc ........................................................................................................................................................................ 269
    OncoVista Innovative Therapies, Inc. ........................................................................................................................................ 270
    OXiGENE, Inc............................................................................................................................................................................ 271
    Patrys Limited ............................................................................................................................................................................ 272
    Peregrine Pharmaceuticals, Inc. ................................................................................................................................................ 273
    Curis, Inc. .................................................................................................................................................................................. 274
    Anadys Pharmaceuticals, Inc .................................................................................................................................................... 275
    ARQULE, INC............................................................................................................................................................................ 276
    ADVENTRX Pharmaceuticals.................................................................................................................................................... 277
    Alexion Pharmaceuticals, Inc..................................................................................................................................................... 278


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(4)
Solid Tumor – Pipeline Review, H1 2012



    Cytokinetics, Inc ........................................................................................................................................................................ 279
    TopoTarget A/S ......................................................................................................................................................................... 280
    Mundipharma International Limited ........................................................................................................................................... 281
    CytRx Corporation ..................................................................................................................................................................... 282
    Regeneron Pharmaceuticals, Inc............................................................................................................................................... 283
    Oncogenex Pharmaceuticals, Inc. ............................................................................................................................................. 284
    Pharmacyclics, Inc..................................................................................................................................................................... 285
    Dendreon Corporation ............................................................................................................................................................... 286
    Array BioPharma Inc. ................................................................................................................................................................ 287
    Thallion Pharmaceuticals Inc. .................................................................................................................................................... 288
    Transgene SA............................................................................................................................................................................ 289
    Progen Pharmaceuticals Limited ............................................................................................................................................... 290
    TapImmune Inc.......................................................................................................................................................................... 291
    Jiangsu Hengrui Medicine Co., Ltd. ........................................................................................................................................... 292
    Threshold Pharmaceuticals, Inc. ............................................................................................................................................... 293
    Galapagos NV ........................................................................................................................................................................... 294
    Synta Pharmaceuticals Corp. .................................................................................................................................................... 295
    CrystalGenomics, Inc. ............................................................................................................................................................... 296
    Natco Pharma Limited ............................................................................................................................................................... 297
    Oasmia Pharmaceutical AB ....................................................................................................................................................... 298
    Algeta ASA ................................................................................................................................................................................ 299
    Protox Therapeutics Inc............................................................................................................................................................. 300
    e-Therapeutics plc ..................................................................................................................................................................... 301
    Rexahn Pharmaceuticals, Inc. ................................................................................................................................................... 302
    SymBio Pharmaceuticals Limited .............................................................................................................................................. 303
    Eisai Inc. .................................................................................................................................................................................... 304
    Morphotek, Inc. .......................................................................................................................................................................... 305
    Spectrum Pharmaceuticals, Inc. ................................................................................................................................................ 306
    Debiopharm Group .................................................................................................................................................................... 307
    Chroma Therapeutics Ltd. ......................................................................................................................................................... 308
    Colby Pharmaceutical Company ............................................................................................................................................... 309
    Affimed Therapeutics AG .......................................................................................................................................................... 310
    Wilex AG ................................................................................................................................................................................... 311
    INSYS Therapeutics, Inc. .......................................................................................................................................................... 312
    Ambit Biosciences Corporation.................................................................................................................................................. 313
    Philogen S.p.A. .......................................................................................................................................................................... 314
    Acceleron Pharma, Inc. ............................................................................................................................................................. 315
    Pieris AG ................................................................................................................................................................................... 316
    Glycotope GmbH ....................................................................................................................................................................... 317
    Neovacs SA ............................................................................................................................................................................... 318
    ERYtech Pharma ....................................................................................................................................................................... 319
    Curacyte AG .............................................................................................................................................................................. 320
    Apogenix GmbH ........................................................................................................................................................................ 321
    BioNumerik Pharmaceuticals, Inc. ............................................................................................................................................. 322


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(5)
Solid Tumor – Pipeline Review, H1 2012



    Altor BioScience Corporation..................................................................................................................................................... 323
    Provecs Medical GmbH ............................................................................................................................................................. 324
    EnGeneIC Ltd ............................................................................................................................................................................ 325
    Angiogene Pharmaceuticals Ltd. ............................................................................................................................................... 326
    GenSpera, Inc. .......................................................................................................................................................................... 327
    Phoenix Biotechnology, Inc. ...................................................................................................................................................... 328
    Allozyne, Inc. ............................................................................................................................................................................. 329
    Coronado Biosciences, Inc. ....................................................................................................................................................... 330
    Cerulean Pharma, Inc................................................................................................................................................................ 331
    MacroGenics, Inc....................................................................................................................................................................... 332
    Pervasis Therapeutics, Inc. ....................................................................................................................................................... 333
    Pharmascience Inc. ................................................................................................................................................................... 334
    Arno Therapeutics, Inc. ............................................................................................................................................................. 335
    ACT Biotech, Inc........................................................................................................................................................................ 336
    OncoMed Pharmaceuticals, Inc. ................................................................................................................................................ 337
    TetraLogic Pharmaceuticals ...................................................................................................................................................... 338
    Boston Biomedical, Inc. ............................................................................................................................................................. 339
    Five Prime Therapeutics, Inc. .................................................................................................................................................... 340
    PanaGin Pharmaceuticals Inc. .................................................................................................................................................. 341
    Vaccinex, Inc. ............................................................................................................................................................................ 342
    Azaya Therapeutics, Inc. ........................................................................................................................................................... 343
    Semafore Pharmaceuticals, Inc. ................................................................................................................................................ 344
    CanBas Co., Ltd. ....................................................................................................................................................................... 345
    S*BIO Pte Ltd ............................................................................................................................................................................ 346
    Merrimack Pharmaceuticals, Inc................................................................................................................................................ 347
    PTC Therapeutics, Inc. .............................................................................................................................................................. 348
    RESprotect GmbH ..................................................................................................................................................................... 349
    Conatus Pharmaceuticals Inc. ................................................................................................................................................... 350
    Deciphera Pharmaceuticals, LLC .............................................................................................................................................. 351
    ProNAi Therapeutics, Inc........................................................................................................................................................... 352
    Mersana Therapeutics, Inc. ....................................................................................................................................................... 353
    Vascular Biogenics Ltd. ............................................................................................................................................................. 354
    Jennerex Biotherapeutics, Inc. .................................................................................................................................................. 355
    Stemline Therapeutics, Inc. ....................................................................................................................................................... 356
    Axelar AB................................................................................................................................................................................... 357
    Endocyte, Inc. ............................................................................................................................................................................ 358
    Proacta, Inc. .............................................................................................................................................................................. 359
    Cornerstone Pharmaceuticals, Inc............................................................................................................................................. 360
    Omnitura Therapeutics Inc. ....................................................................................................................................................... 361
    Advenchen Laboratories, LLC ................................................................................................................................................... 362
    AndroScience Corporation ........................................................................................................................................................ 363
    Onconova Therapeutics, Inc ...................................................................................................................................................... 364
    MolMed S.p.A. ........................................................................................................................................................................... 365
    Intellikine, Inc. ............................................................................................................................................................................ 366


Solid Tumor – Pipeline Review, H1 2012                                                                                                       GMDHC1622IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(6)
Solid Tumor – Pipeline Review, H1 2012



    Syndax Pharmaceuticals, Inc. ................................................................................................................................................... 367
    Myriad Pharmaceuticals, Inc...................................................................................................................................................... 368
    NOXXON Pharma AG ............................................................................................................................................................... 369
    NovaLead Pharma Pvt. Ltd........................................................................................................................................................ 370
    Esperance Pharmaceuticals, Inc. .............................................................................................................................................. 371
    Mirna Therapeutics, Inc. ............................................................................................................................................................ 372
    Transtech Pharma, Inc. ............................................................................................................................................................. 373
    BiPar Sciences, Inc. .................................................................................................................................................................. 374
    Xencor, Inc. ............................................................................................................................................................................... 375
    ImmunoVaccine Technologies Inc. ............................................................................................................................................ 376
    Welichem Biotech Inc. ............................................................................................................................................................... 377
    Oncolys BioPharma Inc. ............................................................................................................................................................ 378
    APEIRON Biologics AG ............................................................................................................................................................. 379
    HENKAN Pharmaceutical Co., Ltd. ........................................................................................................................................... 380
    Immunocore Limited. ................................................................................................................................................................. 381
    BIND Biosciences, Inc. .............................................................................................................................................................. 382
    NewLink Genetics Corporation .................................................................................................................................................. 383
    Tragara Pharmaceuticals, Inc. ................................................................................................................................................... 384
    Taiwan Liposome Company ...................................................................................................................................................... 385
    Drais Pharmaceuticals, Inc. ....................................................................................................................................................... 386
    PharmaMar, S.A. ....................................................................................................................................................................... 387
    Kiadis Pharma B.V. ................................................................................................................................................................... 388
    Quintessence Biosciences, Inc. ................................................................................................................................................. 389
    Bellicum Pharmaceuticals, Inc. .................................................................................................................................................. 390
    VentiRx Pharmaceuticals, Inc. ................................................................................................................................................... 391
    KaloBios Pharmaceuticals, Inc. ................................................................................................................................................. 392
    AB Science ................................................................................................................................................................................ 393
    arGEN-X BV .............................................................................................................................................................................. 394
    Kinex Pharmaceuticals, LLC...................................................................................................................................................... 395
    Adamis Pharmaceuticals Corporation ....................................................................................................................................... 396
    SynDevRx™, Inc. ...................................................................................................................................................................... 397
    Tigris Pharmaceuticals, Inc........................................................................................................................................................ 398
    to-BBB technologies BV ............................................................................................................................................................ 399
    Cylene Pharmaceuticals, Inc. .................................................................................................................................................... 400
    Nereus Pharmaceuticals, Inc. ....
				
DOCUMENT INFO
Description: Solid Tumor – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Solid Tumor - Pipeline Review, H1 2012', provides an overview of the Solid Tumor therapeutic pipeline. This report provides information on the therapeutic development for Solid Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Solid Tumor. 'Solid Tumor - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Solid Tumor. - A review of the Solid Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Solid Tumor pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Solid Tumor. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries